Preventing secondary lymphedema with VEGF-D DNA
AssigneeLudwig Institute for Cancer Research
InventorsLucie Margarete Heinzerling, Megan Elizabeth Baldwin, Steven Alan Stacker, Maro Gregory Achen
Life of this patent
Estimating the term…
Abstract
Methods of preventing secondary lymphedema with DNA encoding VEGF-D and/or VEGF-D protein, and biologically active fragments and analogs thereof, as well as pharmaceutical compositions for treating secondary lymphedema, are presented.
Claims23
A method of treating secondary lymphedema, comprising:
- administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding vascular endothelial growth factor-D (VEGF-D).
A method of treating secondary lymphedema, comprising:
- administering to a patient with secondary lymphedema a therapeutically effective amount of DNA encoding VEGF-D,
- wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.
A method of inhibiting secondary lymphedema, comprising:
- administering to a patient at risk for secondary lymphedema a therapeutically inhibitory amount of DNA encoding VEGF-D.
A method for expressing VEGF-D in a target cell, comprising
- selecting a plasmid capable of expressing DNA encoding VEGF-D, wherein said plasmid has at least one insertion site for insertion of said DNA encoding VEGF-D operably linked to a promoter capable of expression in said target cell;
- inserting said DNA encoding VEGF-D into said insertion site, and introducing said plasmid into said target cell wherein said DNA encoding VEGF-D is expressed at detectable levels.
A method of treating secondary lymphedema, comprising:
- administering to a patient with secondary lymphedema a therapeutically effective amount of at least one plasmid encoding VEGF-DΔNΔC.
A method of treating secondary lymphedema, comprising:
- administering to a patient with secondary lymphedema a therapeutically effective amount of vascular endothelial growth factor-D (VEGF-D) protein.
A method of treating secondary lymphedema, comprising:
- administering to a patient with secondary lymphedema a therapeutically effective amount of VEGF-D protein, wherein said secondary lymphedema is caused by at least one of inflammatory obstruction of lymphatic vessels, neoplastic obstruction of lymphatic vessels, accumulation of ascites fluid due to peritoneal carcinomatosis, and edema of at least one limb.
A method of inhibiting secondary lymphedema, comprising:
- administering to a patient at risk for secondary lymphedema a therapeutically preventative amount of VEGF-D protein.
Dependencies are inferred from the claim text.